Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13459028 | 0.91 | USP2 (0.49) | USP2SMN1; SMN2CYP1A2EPHX1SIGMAR1 | |
| SCHEMBL21358600 | 0.90 | NFE2L2 (0.37) | USP2NFE2L2SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL10552449 | 0.88 | USP2 (0.54) | USP2CYP1A2EPHX1PLA2G2CSIGMAR1 | |
| SCHEMBL13500027 | 0.85 | CYP1A2 (0.41) | USP2NFE2L2SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL21402622 | 0.81 | PRMT5 (0.46) | USP2PRMT5WDR77 | |
| SCHEMBL28432329 | 0.79 | HSD17B10 (0.47) | NFE2L2SMN1; SMN2METAP1CYP1A2EPHX1 | |
| SCHEMBL7401026 | 0.79 | PRMT5 (0.43) | USP2PRMT5WDR77ALDH1A1 | |
| SCHEMBL9238273 | 0.79 | PRMT5 (0.43) | USP2PRMT5WDR77ALDH1A1 | |
| SCHEMBL13500021 | 0.76 | CYP1A2 (0.48) | USP2SMN1; SMN2CYP1A2EPHX1SIGMAR1 | |
| SCHEMBL4630394 | 0.76 | NFE2L2 (0.40) | NFE2L2SMN1; SMN2METAP1CYP1A2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225739-B | Wrinkle-improving agent | 宝丽化成工业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-10813859-B2 | Wrinkle ameliorating agent | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2020-10-27 | — | — | US | disclosed |
| EP-3545942-A1 | WRINKLE AMELIORATING AGENT | Pola Chemical Industries Inc. (JP) | 2019-10-02 | — | — | EP | disclosed |
| US-8829229-B2 | Polyol ethers and process for making them | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2010027663-A1 | POLYOL ETHERS AND PROCESS FOR MAKING THEM | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813859-B2 | Wrinkle ameliorating agent | COL2A1, COL1A1, COL14A1 | USP2 950/4885NFE2L2 51/4885SMN1; SMN2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.